The Centers for Medicare & Medicaid Services (CMS) is moving to significantly reduce payment rates for drugs acquired through the 340B Drug Pricing Program, citing evidence that some patients paid more for the drugs than the hospitals did. The proposed rule, part of the annual hospital outpatient payment update, seeks to adjust reimbursement to the average sales price (ASP) minus 33.4%, a sharp departure from the current rate of ASP plus 6%.
Understanding the 340B Payment Proposal
The 340B program requires pharmaceutical manufacturers to provide outpatient drugs to eligible safety-net hospitals and clinics at a significant discount. Under current federal regulations, Medicare reimburses hospitals for these drugs based on the average sales price plus 6%.
According to the proposed rule released by CMS, the agency identified instances where some patients paid more for the drugs than the hospitals did. By lowering the reimbursement rate to ASP minus 33.4%, the administration intends to align payments more closely with the acquisition costs of the drugs.
Why Safety-Net Hospitals Oppose the Change
Hospital advocacy groups, including those representing nonprofit and academic hospitals, have voiced opposition to the proposal. These institutions argue that the 340B program serves as a critical financial lifeline.
Because the 340B program is restricted to specific nonprofit facilities, for-profit hospitals are ineligible for these discounts. The CMS proposal includes a projected 7.4% increase in payments to for-profit hospitals under the 340B adjustment, a disparity that critics argue will further disadvantage the safety-net providers that rely on the program to sustain their operations.
Historical Context of the 340B Debate
This proposal is the latest swing at what’s become a hotly debated drug discount program, viewed by some as a lifeline for safety net hospitals and by others as a profit center for wealthy health systems.
Key Considerations for Patients and Providers
- Cost-Sharing Impact: The primary justification provided by CMS is the reduction of out-of-pocket costs for Medicare beneficiaries who receive 340B-acquired drugs.
- Financial Sustainability: Nonprofit and academic hospitals maintain that the revenue generated from 340B discounts is essential.
- Regulatory Status: The proposal is currently subject to the federal rulemaking process, meaning the final policy may be subject to change based on public comments and administrative review.
The final rule is expected to shape hospital outpatient reimbursement policies for the coming calendar year, continuing the tension between federal efforts to lower drug costs and the financial needs of safety-net healthcare providers.